Stay updated on Filgotinib and Lanraplenib in Female CLE Clinical Trial
Sign up to get notified when there's something new on the Filgotinib and Lanraplenib in Female CLE Clinical Trial page.

Latest updates to the Filgotinib and Lanraplenib in Female CLE Clinical Trial page
- Check5 days agoChange DetectedThe page adds new help sections (How to Read a Study Record, Common Questions, How to Join a Study) and a recruitment notice indicating no participants are being sought. It also updates the Intervention/Treatment label formatting and the site revision from v3.5.5 to v3.6.0.SummaryDifference0.4%

- Check12 days agoChange DetectedThe page now shows a new software revision label (v3.5.5) in place of the previous one (v3.5.4), reflecting a software version update to the page rendering.SummaryDifference0.0%

- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedLakefront Biotherapeutics NV was added as a collaborator and Galapagos NV was removed from the study's Collaborators and Investigators list.SummaryDifference0.0%

- Check34 days agoChange DetectedThe page's revision tag was updated from v3.5.3 to v3.5.4, indicating a small platform update.SummaryDifference0.0%

- Check55 days agoChange DetectedThe page’s site revision/version indicator was updated from v3.5.2 to v3.5.3.SummaryDifference0.0%

- Check62 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

Stay in the know with updates to Filgotinib and Lanraplenib in Female CLE Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Filgotinib and Lanraplenib in Female CLE Clinical Trial page.